Marinus Pharmaceuticals to Host Hybrid Investor & Analyst Event on Tuesday, September 19, 2023
17 Agosto 2023 - 5:01PM
Business Wire
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical
company dedicated to the development of innovative therapeutics to
treat seizure disorders, will host a hybrid Investor & Analyst
Event on Tuesday, September 19 from 9:00 a.m. to 1:00 p.m. Eastern
Time in New York. The event will feature presentations from Marinus
management and Key Opinion Leaders to discuss the Company’s
clinical pipeline progress, strategic initiatives and business
outlook.
In-person attendance is open to invited research analysts and
institutional investors. All others are invited to watch the live
video webcast. Live questions will be taken by in-person guests,
and virtual participants may submit questions through the webcast
platform.
To register for the video webcast, please visit the Investor
Relations section of the Company's website at
https://ir.marinuspharma.com/events-and-presentations/. A replay of
the webcast will be archived on the Investor Relations section of
the Company's website following the event.
About Marinus Pharmaceuticals Marinus is a commercial
stage pharmaceutical company dedicated to the development of
innovative therapeutics for seizure disorders. The Company’s
commercial product, ZTALMY® (ganaxolone) oral suspension CV, has
been approved by the U.S. FDA for the treatment of seizures
associated with CDKL5 deficiency disorder in patients two years of
age and older. The potential of ganaxolone is also being studied in
other rare seizure disorders, including in Phase 3 trials in
tuberous sclerosis complex and refractory status epilepticus.
Ganaxolone is a neuroactive steroid GABAA receptor modulator that
acts on a well-characterized target in the brain known to have
anti-seizure effects. It is being developed in IV and oral
formulations to maximize therapeutic reach for adult and pediatric
patients in acute and chronic care settings. For more information
visit www.marinuspharma.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230817220888/en/
Molly Cameron Director, Corporate Communications & Investor
Relations Marinus Pharmaceuticals, Inc.
mcameron@marinuspharma.com
Marinus Pharmaceuticals (NASDAQ:MRNS)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Marinus Pharmaceuticals (NASDAQ:MRNS)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024
